Treatment principles
The CARDLESS section for how a treatment plan is intended to be managed — lower-dose care, titration, tapering, maintenance. Asymmetric two-column at desktop: intro left, one ruled list of principle rows right. Rows, not cards, on purpose: an equal-weight card grid makes program limitations compete with the value proposition at the same visual level (the old seven-card “What changes” defect). The disclosure is persistent — always visible, never an accordion — and sources render through ClinicalSourceList.
Copy budgets: sub ≤40 words, principle bodies ≤35 words, at most four rows. Content comes from the catalog overlay's clinicalEducation.regimen.
import from @halwel/ui/components/product/TreatmentPrinciplesSection
Variants
The care strategy
What a lower-dose regimen aims to achieve
A lower-dose regimen uses gradual, response-guided dosing to look for the lowest dose that produces a clinically worthwhile result for the individual.
Start low and move gradually
Smaller adjustments give the clinician more opportunities to assess response and tolerability before changing the dose again.
Let the response guide the dose
The dose does not need to increase automatically. It may be held when the agreed goal is being met and treatment remains tolerable.
Balance benefit and burden
Follow-up considers appetite, weight trend, nutrition, relevant health measures, side effects, and whether ongoing treatment still feels worthwhile.
Reassess over time
If the response is not meaningful, side effects outweigh the benefit, or the goal changes, the clinician can adjust or stop treatment.
Lower-dose does not mean inactive or risk-free. “Microdose” describes Halwel’s care strategy; it is not a standardized medical definition.
- ADA Standards of Care in Diabetes—2026
- Eldor et al., Diabetes Care, 2025 — gradual/flexible titration pilot RCT
The care strategy
What a lower-dose regimen aims to achieve
Gradual, response-guided dosing looks for the lowest dose that produces a clinically worthwhile result.
Start low and move gradually
Smaller adjustments give the clinician more opportunities to assess response and tolerability before changing the dose again.
Let the response guide the dose
The dose does not need to increase automatically. It may be held when the agreed goal is being met and treatment remains tolerable.
Balance benefit and burden
Follow-up considers appetite, weight trend, nutrition, relevant health measures, side effects, and whether ongoing treatment still feels worthwhile.
Lower-dose does not mean inactive or risk-free. “Microdose” describes Halwel’s care strategy; it is not a standardized medical definition.
How this program is managed
Start low and move gradually
Smaller adjustments give the clinician more opportunities to assess response and tolerability before changing the dose again.
Let the response guide the dose
The dose does not need to increase automatically. It may be held when the agreed goal is being met and treatment remains tolerable.
The care strategy
What a laboratory-guided hormone program aims to achieve
A response-guided program pairs each adjustment with follow-up so the dose reflects the person, not the schedule, and stays worth continuing.
Pair every adjustment with a measurement
Each change is followed by a check of symptoms and the relevant laboratory values, so the next decision is made against the person's actual response rather than an assumed schedule of increases.
Hold the dose when the goal is met
When the agreed goal is being met and treatment remains tolerable, the dose may be held rather than escalated, because a larger dose is not automatically a better one for this individual.
Lower-dose does not mean inactive or risk-free. “Microdose” describes Halwel’s care strategy; it is not a standardized medical definition.
- ADA Standards of Care in Diabetes—2026
- Eldor et al., Diabetes Care, 2025 — gradual/flexible titration pilot RCT